Accuracy of commercial panels to evaluate myositis autoantibodies: A single-institution perspective

Ravishankar, Adarsh; Concha, Josef Symon S.; Yan, Daisy; Bax, Christina E.; Yeguez, Andrea C.; Casciola‐Rosen, Livia; Werth, Victoria P.

doi:10.1016/j.jaad.2020.08.111

Cited by 4 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…studied various commercially available MDA‐5 autoantibody assays and discussed their potential limitations and accuracy. Although these assays proved useful in some clinical settings, it was recommended that clinicians should not fully depend on them for patient management 18 . In addition, the completeness of the data is impacted by the retrospective design of the study.…”

Section: Discussionmentioning

confidence: 99%

“…Although these assays proved useful in some clinical settings, it was recommended that clinicians should not fully depend on them for patient management. 18 In addition, the completeness of the data is impacted by the retrospective ª 2021 British Association of Dermatologists design of the study. Assessment of lung and muscle involvement was limited by lack of consistent muscle biopsy and PFT results in some patients, owing to the retrospective design in data collection.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical and histopathological features of adult patients with dermatomyositis and melanoma differentiation associated‐5 autoantibody seropositivity status, as determined by commercially available testing: a retrospective, single‐institution comparative cohort study

Shakshouk

Deschaine

Wetter

et al. 2021

Clin Experimental Derm

View full text Add to dashboard Cite

Background. Although melanoma differentiation associated (MDA)-5 autoantibodies have been widely explored in dermatomyositis (DM), most studies have relied on MDA-5 autoantibody testing performed in research settings, rather than the nowavailable commercial laboratory tests. Aim. To characterize the clinical and histopathological data in patients with DM and circulating MDA-5 autoantibodies, as defined by commercially available testing. Methods. This was a retrospective review of patients with DM who underwent MDA-5 antibody testing. All available skin biopsy slides were reviewed. Results. Cutaneous features more prevalent in MDA-5-positive DM included Raynaud phenomenon (RP) (P < 0.001), cutaneous ulcerations (P = 0.01), mechanic hands (P < 0.02), palmar papules (P < 0.01), oral ulcers (P = 0.024) and alopecia (P = 0.03). Joint and pulmonary involvement were more common in patients with MDA-5-positive DM (both P < 0.001) as was dysphagia (P < 0.01). Myopathy (P = 0.4) and malignancy (P = 0.34) were not statistically different between the cohorts. Vasculopathy was more common in MDA-5-positive DM (P < 0.01), while spongiosis was less common (P < 0.02). Conclusion. This study not only confirms some known associations between disease manifestations and MDA-5 autoantibody status, as determined by commercially available tests, but also identifies new associations, including RP and dysphagia.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Clinical and histopathological features of adult patients with dermatomyositis and melanoma differentiation associated‐5 autoantibody seropositivity status, as determined by commercially available testing: a retrospective, single‐institution comparative cohort study

Shakshouk

Deschaine

Wetter

et al. 2021

Clin Experimental Derm

View full text Add to dashboard Cite

show abstract

“…However, many patients with DM do not test positive for antibodies on commercial myositis panels. 7 In conclusion, anasarca and hyponatremia can be rare complications of DM. This phenotype may require immunosuppression with second-line agents and coordination of care with multidisciplinary teams.…”

Section: Discussionmentioning

confidence: 92%